Preparation of a microcrystalline suspension formulation of Lys(B28)pro(B29)-human insulin with ultralente properties

Journal of Pharmaceutical Sciences

Volumn 88, Issue 9, 1999, Pages 861-867

  Richards, Jane P ^a,e   Stickelmeyer, Mary P ^a   Frank, Bruce H ^a   Pye, Susan ^b   Barbeau, Michelle ^b   Radziuk, Jerry ^b   Smith, G David ^c,d   Defelippis, Michael R ^a  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF OTTAWA   (Canada)

^c HAUPTMAN WOODWARD MEDICAL RESEARCH INSTITUTE   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e Baxter Hemoglobin Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMULIN U; INSULIN LISPRO; INSULIN ZINC SUSPENSION; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONFORMATIONAL TRANSITION; CRYSTALLIZATION; DOG; DRUG ACTIVITY; DRUG CONFORMATION; DRUG FORMULATION; DRUG SYNTHESIS; NONHUMAN; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032868958     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1021/js990107o     Document Type: Article

References (28)

1. max is attained; (UHI), ultralente human insulin; ULP, ultralente LysPro; ULP C/S, ultralente LysPro concentrated suspension.
2. Hallas-Møller, K.; Petersen, K.; Schlichtkrull, J. Crystalline and Amorphous Insulin-Zinc Compounds with Prolonged Action. Science 1952, 116, 394-398.
3. Hallas-Møller, K. The Lente Insulins. Diabetes 1956, 5, 7-14.
4. Hagedorn H. C.; Jensen, B. N.; Krarup, N. B.; Wodstrup, I. Protamine Insulinate. J. Am. Med. Assoc. 1936, 106, 177-180.
5. Krayenbühl, C.; Rosenberg, T. Crystalline Protamine Insulin. Rep. Steno Mem. Hosp. Nord. Insulinlab 1946, 1, 60-73.
6. B29]-Human Insulin Analogue. J. Pharm. Sci. 1998, 87, 170-176.
7. B29-Human Insulin. Structure 1995, 3, 615-622.
8. Kaarsholm, N. C., Ko, H.-C., Dunn, M. F. Comparison of Solution Structural Flexibility and Zinc Binding Domains for Insulin, Proinsulin, and Miniproinsulin. Biochemistry 1989, 28, 4427-4435.
9. B29-Insulin: Dissociation of a Protein-Ligand Complex. Protein Sci. 1996, 5, 2521-2531.
10. B29-Insulin Hexamers: A Comparison Study. Pharm. Res. 1997, 14, 25-36.
11. Richards, J. P.; Stickelmeyer, M. P.; Flora, D. B.; Chance, R. E.; Frank, B. H.; DeFelippis, M. R. Self-Association Properties of Monomeric Insulin Analogues Under Formulation Conditions. Pharm. Res. 1998, 15, 1434-1441.
12. Derewenda, U.; Derewenda, Z.; Dodson, E. J.; Dodson, G. G.; Reynolds, C. D.; Smith, G. D.; Sparks, C.; Swenson, D. Phenol Stabilizes More Helix in a New Symmetrical Zinc Insulin Hexamer. Nature 1989, 338, 594-596.
13. 6 Insulin/Phenol Complex. Proteins, Struct. Funct. Genet. 1992, 14, 401-408.
14. 3 Human Insulin Hexamer. Biochemistry 1994, 33, 1512-1517.
15. Smith, G. D.; Swenson, D. C.; Dodson, E. J.; Dodson, G. G.; Reynolds. C. D. Structural Stability in the 4-Zinc Human Insulin Hexamer. Proc. Natl. Acad. Sci. U.S.A. 1984, 81, 7093-7097.
16. Baker, E. N.; Blundell, T. L.; Cutfield, J. F.; Cutfield, S. M.; Dodson, E. J.; Dodson, G. G.; Crowfoot Hodgkin, D. M.; Hubbard, R. E.; Isaacs, N. W.; Reynolds, C. D.; Sakabe, K.; Sakabe, N.; Vijayan, N. M. The Structure of 2Zn Pig Insulin Crystals at 1.5 A Resolution. Philos. Trans. R. Soc. London B 1988, 319, 369-456.
17. Yip, C. M.; DeFelippis, M. R.; Frank, B. H.; Brader, M. L.; Ward, M. D. Structural and Morphological Characterization of Ultralente Insulin Crystals by Atomic Force Microscopy: Evidence of Hydrophobically Driven Assembly. Biophys. J. 1998, 75, 1172-1179.
18. Brange, J.; Skelbaek-Pedersen, B.; Langkjaer, L.; Damgaard, U.; Ege, H.; Havelund, S.; Heding, L. G.; Jørgensen, K. H.; Lykkeberg, J.; Markussen, J.; Pingel, M.; Rasmussen, E. Galenics of Insulin. The Physicochemical and Pharmaceutical Aspects of Insulin and Insulin Preparations; Springer-Verlag: Berlin, Heidelberg, 1987.
19. Capel, M. 1998, X12B Software, http://crim12b.nsls.bnl.gov/ x12b_downloads.html.
20. Smith, G. D.; Ciszak, E. The Structure of a Complex of Hexameric Insulin and 4′-Hydroxyacetanilide. Proc. Natl. Acad. Sci. U.S.A 1994, 91, 8851-8855.
21. Smith, G. D.; Ciszak, E.; Pangborn, W. A Novel Complex of a Phenolic Derivative with Insulin: Structural Features Related to the T → R Transition. Protein Sci. 1996, 5, 1502-1511.
22. Blessing, R. H. Data Reduction and Error Analysis for Accurate Single-Crystal Diffraction Intensities. Crystallogr. Rev. 1987, 1, 3-58.
23. Schlichtkrull, J. Insulin Crystals IV. The Preparation of Nuclei, Seeds and Monodisperse Insulin Crystal Suspensions. Acta Chem. Scand. 1957, 11, 299-302.
24. Kadima, W.; McPherson, A; Dunn M. F.; Jurnak, F. Precrystallization Aggregation of Insulin by Dynamic Light Scattering and Comparison with Canavalin. J. Cryst. Growth 1991, 110, 188-194.
25. Bentley G.; Dodson G.; Lewitova, A. Rhombohedral Insulin Crystal Transformations. J. Mol. Biol. 1978, 126, 871-875.
26. Reynolds, C. D.; Stowell, B.; Joshi, K. K.; Harding, M. M.; Maginn, S. J.; Dodson G. G. Preliminary Study of a Phase Transformation in Insulin Crystals Using Synchrotron-Radiation Laue Diffraction. Acta Crystallogr. 1988, B44, 512-515.
27. Seigler, D. E.; Olsson, G. M.; Agramonte, R. F.; Lohman, V. L.; Ashby, M. H.; Reeves, M. L.; Skyler, J. S. Pharmacokinetics of Long-acting (Ultralente) Insulin Preparations. Diab. Nutr. Metab. 1991, 4, 267-273.
28. Schernthaner, G. Immunogenicity and Allergenic Potential of Animal and Human Insulins. Diabetes Care 1993, 16, 155-165.